Trial | NCT00035074  Report issue

Official Title

A Pharmacokinetic Study to Determine the Oral Bioavailability of Methotrexate in Patients With Inflammatory Bowel Disease

  • Phase

    N/A

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    naltrexone ...

  • Study Participants

    None
Patients with inflammatory bowel disease (IBD) who require methotrexate (MTX)for treatment currently receive this drug by injection. MTX is also available as a pill that can be given by mouth but it is not known how well the drug enters the body in patients with Crohn's disease or ulcerative colitis. This study is being done to compare how much MTX enters the body when the drug is taken by mouth compared to when it is given by injection. If the drug is well absorbed, it may allow patients to receive the drug by mouth.
Study Started
May 02
2002
Last Update
Jun 24
2005
Estimate

Drug Methotrexate

Criteria 

Adult or pediatric patients with IBD (CD or UC) currently receiving MTX as part of their clinical care.
Patients must be receiving weekly MTX at a dose between 7.5 and 40 mg/m2.
Weight >= 12 kg.
Normal serum creatinine.
No Results Posted